The Bottom Line Ipamorelin is a pentapeptide GH secretagogue that activates the GHS-R1a (ghrelin) receptor to release growth hormone without stimulating cortisol, ACTH, or prolactin, a selectivity profile documented at doses 200-fold above its effective GH-releasing dose
Oncology drugs, which often qualify for Priority Review and Breakthrough Therapy designation, can exit clinical development faster
The enforcement grace periods ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities
Instead, I decided to focus on building something sustainable
The STEP (Semaglutide Treatment Effect in People with obesity) trials showed that participants lost approximately 1520% of their body weight over 68 weeks, with body composition analyses indicating that roughly 2040% of the total weight lost was lean mass